Sciensus

What Sciensus does

Sciensus is a UK-headquartered, privately held life sciences organization that provides integrated clinical and commercial services to biopharmaceutical companies, health systems (notably the NHS), and patients across 15+ European countries. The company's core offering combines human-led clinical homecare — including at-home cancer treatment delivery (400+ SACT regimens annually to 4,000 patients), specialist nursing, blood monitoring, and aseptic compounding — with a proprietary digital platform built around an "integrated intelligence engine" that aggregates real-world data from 70+ million patient interactions to power predictive analytics, patient engagement (via the Sciensus Intouch app), and outcomes tracking. The post-January 2024 acquisition of Vinehealth added oncology-specific symptom tracking and patient engagement capabilities, while the December 2025 CareTranscribe pilot extended the platform into AI-supported clinical documentation.

The business operates four interlocking revenue streams: biopharma commercial services (market access consulting, regulatory support, early access programs, pharmacovigilance, clinical trial support), NHS and health system managed services (clinical homecare, medication delivery, capacity relief), pharmaceutical distribution and wholesale (GDP-compliant storage, last-mile delivery, $400M in annual orphan drug trading volume), and digitally-enabled patient support programs funded by biopharma partners. The company is primarily domiciled as Sciensus Pharma Services Limited (England & Wales), with Sciensus International B.V. in the Netherlands and three Swiss subsidiaries (Sciensus AG, Sciensus Apotheke AG, Sciensus Wholesale AG) supporting Spitex homecare, pharmacy, and wholesale operations.

Sciensus serves approximately 300,000 patients annually across 70+ therapy areas through a network of 4,000+ hospital, clinic, and pharmacy partners, holding certifications including ISO 27001, ISO 27701, CQC registration, NHS DSPT compliance, Swissmedic wholesale licensing, and GDP certification. The company maintains a multi-language digital presence (English, German, French, Spanish, Italian) and is governed by an executive team including CEO Christian Tucat, Chief Clinical Officer Jonathan Asbridge, Chief Medical Officer Sameer Mistry, and non-executive director Doug Oppenheim, with recent senior additions including Managing Director of Rare & Specialty Julie Gosper and General Counsel Annabelle Newman.

Name

Sciensus

Legal name

Sciensus Pharma Services Limited

Website

https://sciensus.com

Company type

Private

Founded year

1995

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Sciensus is a UK-headquartered private life sciences company delivering integrated clinical homecare, pharmaceutical distribution, and real-world data services to biopharma companies, health systems (notably the NHS), and 300,000+ patients annually across 15+ European countries.

Ownership category

akta.pro rank

Product category

Clinical Homecare Services

NAICS

Home Health Care Services (62161), Scientific Research and Development Services (5417)

SIC

Services-Home Health Care Services (8082), Services-Health Services (8000), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Home-Based Chronic Disease Management (Skilled) (HLADAFAL)

akta.pro secondary industries

Market Access, Pricing & Reimbursement (Evidence Generation) FSP (HLAGAOAN), Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF) (HLAGAJAM)

Keywords

• Clinical homecare services
• Pharmaceutical distribution
• Patient support programs
• Real-world evidence generation
• Market access consulting

Headquarters

HQ city

Brighton

HQ country

United Kingdom

HQ region

Europe

Offices7 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Supply Chain, Infrastructure, Technology or R&D, Marketing or Sales

Revenue model

1. Biopharma Commercial Services: Sciensus provides integrated commercial services to pharmaceutical and biotech companies including market access support, early access programs, regulatory consulting, supply chain management, and real-world evidence generation. Revenue is derived from service fees charged to biopharma partners for helping them navigate European markets, launch therapies, and commercialize products. Services span the product lifecycle from early access through full commercialization.
2. Healthcare System Services: Sciensus provides clinical homecare, nursing services, and medication delivery to health systems (NHS in the UK) under contract. Revenue is generated through service agreements with public healthcare providers for delivering care at home, reducing hospital burden, and improving patient outcomes. Services include cancer care at home, blood monitoring, e-prescriptions, and clinical screening services.
3. Pharmaceutical Distribution: End-to-end pharmaceutical storage, distribution, and delivery services across Europe. Sciensus handles import, title management, last-mile delivery, and order-to-cash operations. Revenue is derived from distribution fees and margins on drug trading, with $400m of orphan drugs traded annually.
4. Patient Support Programs: Digitally-enabled patient support programs combining nurse support with digital tools to improve medication adherence and persistence. These programs are typically funded by biopharma partners as part of market access and commercialization strategies.

Go-to-market motion3 records

Distribution channels5 records

Marketing channels6 records

Core offering

Sciensus provides integrated clinical homecare, pharmaceutical supply chain, and patient support services to biopharma companies and health systems across Europe. The company combines specialist nursing, at-home medication delivery, patient support programs, and real-world evidence generation through a proprietary digital platform. It supports 300,000+ patients annually across cancer, chronic conditions, and rare diseases, distributing $400 million of orphan drugs each year.

Product overview

Sciensus is a leading life sciences organization providing integrated commercial services across Europe, combining human-led patient care with advanced digital solutions. The core offering consists of the Digital Solutions Platform powered by a proprietary integrated intelligence engine, complemented by the Sciensus Intouch mobile app for patients. The portfolio spans end-to-end pharmaceutical services (supply chain, storage, distribution, dispense and delivery), clinical services (nursing, clinical homecare, cancer care, compounding), and evidence generation (real-world data, clinical trials, pharmacovigilance). Following the January 2024 acquisition of Vinehealth, Sciensus expanded its digital health capabilities with cancer-focused symptom tracking and patient engagement tools. Services are organized around three therapeutic areas: cancer, chronic conditions, and rare and specialty diseases, serving over 300,000 patients annually across more than 4,000 healthcare relationships in Europe.

Differentiator

Problem solved

Functional benefit

Brands

• Sciensus Intouch: Mobile application providing Sciensus patients with functionality to manage their treatment and interactions with Sciensus, including viewing treatment information, obtaining condition-related information, and scheduling deliveries.
• Vinehealth

Products and services

• Supply Chain Management End-to-end supply chain services including procurement, logistics coordination, and inventory management for pharmaceutical products across Europe.
• Pharmaceutical Storage and Distribution Temperature-controlled GDP-compliant storage and pan-European distribution of pharmaceuticals, including orphan and specialty medicines.
• Dispense and Delivery Safe, compliant medication dispensing and last-mile delivery services across Europe, covering import, title management, and patient delivery.
• Patient Support Programmes Digitally-enabled patient support programs combining human care with digital tools to improve medication adherence, persistence, and treatment outcomes.
• Nursing and Clinical Services Specialist nurse visits and clinical support for patients at home, including medication administration, patient education, and clinical monitoring.
• Clinical Homecare At-home clinical care delivery including cancer treatment administration and monitoring by specialist nurses.
• Real-World Data Collection and analysis of real-world evidence and patient data to support evidence generation, HTA submissions, and strategic decision-making for biopharma.
• Early Access Programmes Managed early access programs helping patients access medicines before full regulatory approval, including compassionate use and named patient supply.
• Pharmacovigilance Services Post-market safety surveillance, adverse event reporting, and compliance with pharmacovigilance requirements for pharmaceutical clients.
• Clinical Trials Decentralized clinical trial services and clinical study support, extending study reach and capturing real-world insights.
• Cancer Care at Home At-home cancer care delivering over 400 SACT regimens annually for 4,000 patients through specialist nurses and dedicated compounding units.
• Aseptic Compounding Specialist aseptic compounding services for custom medications, particularly for cancer treatments administered at home.
• Market Access Consulting Strategic consulting to navigate Europe's complex regulatory, pricing, and reimbursement systems to accelerate market access.
• Regulatory Approval Consulting Expert guidance through regulatory approval processes across European markets.
• Sciensus InTouch App Mobile and tablet application enabling patients to manage their treatment, view condition information, schedule deliveries, access resources, and communicate with the care team. Available on iOS and Android.
• Digital Solutions Platform Proprietary integrated intelligence engine combining human care with advanced digital solutions, powering patient engagement, clinical connectivity, and real-world data collection.
• Vinehealth Digital Platform Cancer-focused patient and physician support platform offering symptom tracking, medication management, and patient engagement tools, designed for oncology care. Acquired by Sciensus in January 2024.

Quantifiable outcome

• Improves medication adherence by over 10% for chronic conditions patients through combined digital tools and nurse support
• +4 more outcomes

Named customers3 records

Segments6 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature6 records

Partnerships

Five partnerships are on record, tiered minor, strategic and core.

• Rare Patient VoiceminorStrategic or Co-development Partner · 1 December 2025Collaboration to conduct a European survey of 217 rare disease patients and caregivers across France, Germany, Italy, the UK, and Spain in December 2025. The survey examined patient access gaps and care pathway challenges, with findings highlighting the disconnect between therapeutic innovation and outdated access pathways. The partnership demonstrates Sciensus commitment to understanding patient needs and generating evidence for improved care models.
• VinehealthstrategicTechnology or Integration · 1 January 2024Acquired in January 2024, Vinehealth is a health tech business offering cancer-focused patient and physician support platforms. The acquisition enhances Sciensus digital capabilities with symptom tracking, medication management, and patient engagement tools specifically designed for oncology. The integration aims to improve treatment visibility, patient outcomes, and data collection for cancer care improvement.
• NHS (National Health Service)coreStrategic or Co-development PartnerSciensus works in collaboration with the NHS to deliver clinical homecare services, reduce hospital capacity pressures, and provide efficient medication delivery solutions. The partnership involves NHS trusts referring patients for at-home treatment, with Sciensus handling medication dispensing, delivery, nursing visits, and ongoing patient support. Services include cancer care at home, blood monitoring, and e-prescription services that relieve NHS system burden while improving patient outcomes.
• Healthcare ProfessionalscoreStrategic or Co-development PartnerNetwork of doctors, nurses, specialists, and other healthcare professionals who refer patients to Sciensus services and collaborate on patient care delivery. Healthcare professionals maintain clinical oversight while Sciensus provides home-based care, medication management, and digital support tools. The partnership enables clinicians to monitor patient progress through real-world data while patients receive convenient at-home treatment.
• Pharmaceutical and Biotech CompaniescoreStrategic or Co-development PartnerBiopharma partnerships form the core of Sciensus business model. The company provides integrated commercial services including market access support, early access programs, regulatory consulting, supply chain management, patient support programs, and real-world evidence generation. Partnerships span from early development through full commercialization, helping biopharma companies maximize patient access to therapies across European markets.

Scale indicators11 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Thermo Fisher Scientific (PPD): Through its PPD clinical research business, Thermo Fisher provides biopharma services including clinical trials, real-world evidence, and post-approval support. Overlaps with Sciensus' decentralized trials and RWE services at the upper end of scale and capability.
• Cencora: Global pharmaceutical distribution and solutions business (formerly AmerisourceBergen) with specialty distribution, patient services, and consulting capabilities. Comparable on GDP-compliant distribution, patient support programmes, and biopharma services across Europe.
• Syneos Health: Contract research and commercial organization providing clinical trial services, market access, and biopharma commercialization. Overlaps with Sciensus on decentralized trials, real-world evidence, and biopharma commercial services, though at much larger scale.
• IQVIA: Global life sciences services and clinical research giant with significant real-world evidence, market access, and biopharma commercialization capabilities. Competes with Sciensus on RWE generation, clinical trials, and pan-European commercial service contracts but at substantially greater scale.
• Inizio: Specialty pharma services platform formed by the combination of Ashfield and other commercialization businesses, offering market access, medical affairs, and patient engagement at global scale. Broader and larger incumbent competing for the same biopharma commercial services spend.
• ICON plc: Global CRO offering clinical research, real-world evidence, and commercial services to biopharma. Comparable on clinical trial delivery, RWE generation, and post-approval evidence work but with materially greater scale and geographic breadth.

Direct peers

• PharmaLex: Specialty pharma services provider focused on regulatory affairs, market access, and evidence generation for biopharma clients across Europe. Overlaps with Sciensus' market access consulting, regulatory approval consulting, and real-world evidence services.
• LloydsPharmacy Clinical Homecare: UK provider of clinical homecare and specialty pharmaceutical services for NHS and private patients. Directly comparable on home-based chronic disease management, nursing services, and pharmaceutical dispensing delivered to patients at home.
• HealthNet Homecare: UK specialist clinical homecare provider delivering hospital-level treatments, including home infusions and oncology support, to NHS and private patients. Highly comparable in service line, customer base, and therapeutic focus on chronic and rare disease management.
• Clinigen: UK-headquartered specialty pharma services group providing clinical homecare, market access, and early access programmes across Europe. Closest direct comparable in size, geography, and service mix; Sciensus' new Rare & Specialty MD Julie Gosper was recruited from Clinigen, underscoring the overlap.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/Sciensus_Group
• YouTubeyoutube.com/@sciensus/featured
• Facebookfacebook.com/SciensusGroup
• LinkedInlinkedin.com/company/sciensus

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sciensus